Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 20, Issue 2, 1999, Pages 137-146

  Strawford, Alison ^a,b   Barbieri, Teresa ^c   Neese, Richard ^a   Van Loan, Marta ^c   Christiansen, Mark ^d   Hoh, Rebecca ^d   Sathyan, Gayatri ^e   Skowronski, Roman ^e   King, Janet ^c   Hellerstein, Marc ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c W Human Nutrition Research Center   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ALZA CORPORATION   (United States)

Author keywords

AIDS wasting syndrome; Anabolic therapies; Androgens; De novo lipogenesis; Hypothalamic hypogonadism; Lean body mass; Testosterone

Indexed keywords

NANDROLONE; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; LEAN BODY WEIGHT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; WASTING SYNDROME; WEIGHT REDUCTION;

EID: 0033081264     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199902010-00005     Document Type: Article

References (48)

1. Kotler DP, Wang J, Pierson R. Studies of body composition in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 1985;42:1255-65.
2. Hellerstein M. Pathophysiology of the AIDS-wasting syndrome: implications for therapy. In Jäger H ed. Wasting und AIDS: die Behandlung der HIV-bedingten Kachexie. Stuttgart: Georg Thieme, 1997:5-16.
3. Chlebowski RT, Grosvenor MB, Bernhard NH, et al. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol 1989;84:1288-93.
4. Lindan CP, Allen S, Serufilira A, et al. Predictors of mortality among HIV infected women in Kigali, Rwanda. Ann Intern Med 1992;116:320-8.
5. Guenter P, Murahainen N, Simons G, et al. Relationships among nutritional status, disease progression and survival in HIV infection. J AIDS 1993;6:1130-8.
6. Suttmann U, Okcenga J, Selberg O, Hoogestraat L, Deicher H, Muller MJ. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected out-patients. J Acquir Immun Defic Syndr Hum Retrovirol 1995;8:2338-46.
7. Kotler DP, Tierney A, Wang J, et al. Magnitude of body cell mass depletion and timing of death from wasting in AIDS. Am J Clin Nutr 1989;50:444-7.
8. Kotler DP, Tierney A, Culpepper-Morgan J, et al. Effect of home total pareneteral nutrition on body composition in patients with acquired immunodeficiency syndrome. JPEN J Parent Enteral Nutr 1990;14:454-8.
9. Hellerstein MK, Kahn J, Mudie H. Current approach to the treatment of HIV associated weight loss: pathophysiologic considerations and emerging management strategies. Semin Oncol 1990;17(Suppl 9):17-33.
10. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS related cachexia. Ann Intern Med 1994;121: 393-9.
11. Oster MH, Enders SH, Samuels ST, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994;121: 400-8.
12. Hellerstein MK, Grunfeld C, Wu K, et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993:76:559-65.
13. Hellerstein MK, Wu K, Kaempfer S, et al. Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immunodeficiency syndrome: relation to indices of cytokine production. J Acquir Immun Defic Syndr Hum Retrovirol 1996;11:258-70.
14. Hoh R, Pelfini A, Neese RA, et al. De novo lipogenesis predicts short-term body composition response by bioelectrical impedance analysis to oral nutritional supplements in HIV-associated wasting. Am J Clin Nurr 1998;68:154-63.
15. Mulligan K, Grunfeld C, Hellerstein MK, et al. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;77:956-62.
16. Hommes MJT, Romijn JA, Endert E, Sauerwein HP. Resting energy expenditure and substrate oxidation in human immunodeficiency virus (HIV)-infected asymptomatic men: HIV affects host metabolism in the early asymptomatic stage. Am J Clin Nutr 1991; 54:311-5.
17. Dobs AS, Dempsey MA, Landenson PW, et al. Endocrine disorders in men infected with HIV. Am J Med 1988;84:611-6.
18. Coodley G, Loveless M, Merrill T. The HIV wasting syndrome: a review. J Acquir Immun Defic Syndr 1994;7:681-94.
19. Christef N, Gharakhanian S, Thobie N, et al. Evidence for changes in adrenal function and testicular steroids during HIV infection. J Acquir Immun Defic Syndr 1992;5:841-6.
20. Villette JM, Bourin P, Doinel C, et al. Circadian variations in plasma levels of hypophyseal, adrenocortical and testicular hormones in men infected with HIV. J Clin Endocrinol Metab 1990; 70:572-7.
21. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. Ann Intern Med 1996;125:873-82.
22. Grinspoon S, Corcoran C, Lee K, et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 1996;81:4051-8.
23. Vermeulen A. Environment, human reproduction, menopause and andropause. Env Health Perspectives 1993;101(Suppl 2):91-100.
24. Fruth SJ, Worrell TW. Factors associated with menstrual irregularities and decreased bone mineral density in female athletes. J Orthop Sports Phys Ther 1995;22:26-38.
25. Nindl B, Friedl K, Frykman P, et al. Physiologic recovery after severe weight loss. FASEB J 1994;8:A724.
26. Woolf PD, Hamill RW, McDonald J, Lee LA, Kelly M. Transient hypogonadotrophic hypogonadism caused by critical illness. J Clin Endocrinol Metab 1985;60:444-50.
27. Wijnard HP, Bosch AM, Donker CW. Pharmacokinetic parameters of nandrolone (19-nortestosterone) after intramuscular administration of decanoate (Deca-Durabolin) to healthy volunteers. Acta Endocrinol 1985;71(Suppl 2):19-30.
28. Harris JA, Benedict FG. The variation and statistical constants of basal metabolism in men. J Biol Chem 1921;121:257-79.
29. Berner DL, Brown J. Protein nitrogen combustion method collaborative study 1. Comparison of Smalley total Kjeldahl nitrogen and combustion results. J Am Oil Chem Soc 1994;71:1291-3.
30. Cook JGH. Factors influencing the assay of creatinine. Ann Clin Biochem 1975;12:219.
31. Forbes GB. Influence of hormones. In Forbes GB, ed. Human body composition: growth, aging, nutrition and activity. New York: Springer-Verlag, 1987:267-74.
32. Bagnati R, Fanelli R. Determination of 19-nortestosterone, testosterone, and trenbolone by gas chromatography-negative ion-mass spectrometry after formation of the pentafluorobenzyl carboxy-methoxime-trimethylsilyl derivatives. J Chromatogr 1991;547: 325-34.
33. Hellerstein MK, Christiansen M, Kaempfer S, et al. Measurement of de novo hepatic lipogenesis in humans using stable isotopes. J Clin Invest 1991;87;1841-52.
34. Hellerstein MK, Schwarz J-M, Neese RA. Regulation of hepatic de novo lipogenesis in humans. Ann Rev Nutr 1996;16:523-57.
35. Pencharz PB, Azcue M. Use of bioelectrical impedance analysis measurements in the clinical management of malnutrition. Am J Clin Nutr 1996;64(Suppl):485s-8s.
36. Mazess RB, Barden HS, Bisek JP, et al. Dual-energy x-ray absorptiometry for total body and regional bone-mineral and soft tissue composition. Am J Clin Nutr 1990;51:1106-12.
37. Randall H. Water, electrolytes, and acid-base balance. In Shils ME, Young CR, eds. Modern nutrition in health and disease, 7th ed. Philadelphia: Lea & Febiger, 1988:118-9.
38. Wynn A, Wynn M. The effects of food shortage on human reproduction. Nutr Health 1993;9:43-52.
39. Grinspoon S, Corcoran C, Lee K, et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 1996;81:4051-8.
40. Coodley GO, Coodley MK. A trial of testosterone therapy for HIV-associated weight loss. AIDS 1997;11:1347-52.
41. Grunfeld C, Feingold K. Metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 1991;3:143-58.
42. Macallan D, McNurlan M, Calder A, Garlick P. Whole body protein turnover from leucine kinetics and the response to nutrition in human immunodeficiency virus infection. Am J Clin Nutr 1995; 61:818-26.
43. Bhasin S, Stoner TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997;82:407-13.
44. Bhasin S, Storer T, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335:1-7.
45. Bergink EW, Geelen JAA, Turpisn EW. Metabolism and receptor binding of nandrolone and testosterone under in vitro and in vivo conditions. Acta Endocrinol 1985;271(Suppl):31-7.
46. Overbeek GA. Anabole Steroide. Chemiu under Pharmakologies. Berlin: Springer-Verlag, 1966.
47. Toth M, Zakar T. Relative binding affinities of testosterone, 19-nortestosterone and their 5α derivatives to the androgen receptor and to other androgen-binding proteins: a suggested role of 5α-reductive steroid metabolism in the dissociation of "myotropic" and "androgenic" activities of 19-nortestosterone. J Steroid Biochem 1982;17:653-60.
48. Wilson J. Androgens. In Goodman LS, Gilman A, Rall TW, Niew A-S, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: Pergamon Press, 1990: 1413-30.